Relmada Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell RLMD and other ETFs, options, and stocks.About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications.
CEOSergio Traversa
CEOSergio Traversa
Employees17
Employees17
HeadquartersCoral Gables, Florida
HeadquartersCoral Gables, Florida
Founded2012
Founded2012
Employees17
Employees17
RLMD Key Statistics
Market cap317.53M
Market cap317.53M
Price-Earnings ratio-2.31
Price-Earnings ratio-2.31
Dividend yield—
Dividend yield—
Average volume1.01M
Average volume1.01M
High today$4.41
High today$4.41
Low today$4.15
Low today$4.15
Open price$4.16
Open price$4.16
Volume2.76M
Volume2.76M
52 Week high$5.12
52 Week high$5.12
52 Week low$0.2404
52 Week low$0.2404
Stock Snapshot
With a market cap of 317.53M, Relmada Therapeutics(RLMD) trades at $4.35. The stock has a price-to-earnings ratio of -2.31.
On 2025-12-19, Relmada Therapeutics(RLMD) stock moved within a range of $4.15 to $4.41. With shares now at $4.35, the stock is trading +4.8% above its intraday low and -1.4% below the session's peak.
Trading activity shows a volume of 2.76M, compared to an average daily volume of 1.01M.
The stock's 52-week range extends from a low of $0.24 to a high of $5.12.
The stock's 52-week range extends from a low of $0.24 to a high of $5.12.
RLMD News
TipRanks 4d
Relmada Therapeutics Amends Executive Employment AgreementsClaim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
People also own
Based on the portfolios of people who own RLMD. This list is generated using Robinhood data, and it’s not a recommendation.